Vimarsana
Biggest News Aggregation in the World

Gnubiotics Sciences Sa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gnubiotics Sciences Sa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gnubiotics Sciences Sa Today - Breaking & Trending Today

DelveInsight Business Research, LLP: Microbiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain - Vimarsana News

DelveInsight Business Research, LLP: Microbiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain

Microbiome clinical trial pipeline constitutes 130+ key companies continuously working towards developing 200+ microbiome drugs, analyzes DelveInsight LAS VEGAS, Nov. 9, 2022 /PRNewswire/

Microbiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain - Vimarsana News

Microbiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain

/PRNewswire/ -- DelveInsight's 'Microbiome Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

Gnubiotics gains allowance of patent of microbiome markers for prediction, identification and treatment of pet obesity from the European Patent Office - Vimarsana News

Gnubiotics gains allowance of patent of microbiome markers for prediction, identification and treatment of pet obesity from the European Patent Office

Gnubiotics gains allowance of patent of microbiome markers for prediction, identification and treatment of pet obesity from the European Patent Office USA - English Share this article Share this article LAUSANNE, Switzerland, May 24, 2021 /PRNewswire/ -- Gnubiotics Sciences SA (Gnubiotics), a Swiss biotech company pioneering novel microbiome targeted solutions for humans and companion animals, today announced the allowance from the European Patent Office (EPO) for its patent application 19812838.1 (EPO pubication 3695018). This is a key patent filing covering the microbiome-based prediction, ...